Biography
Dr. Tse earned a Bachelor of Arts degree in Biology from the Brown University Program in Liberal Medical Education in 1991, and then graduated with an M.D. degree from SUNY Stony Brook Medical School in 1995. Dr. Tse completed a neurology residency at Mount Sinai Medical Center in 1999, and in the final year served as a Chief Resident. She completed a fellowship in electromyography at the New York-Cornell Presbyterian Medical Center. She worked at Maimonides Hospital in Brooklyn from 2000 to 2002, where she saw a variety of movement disorders.
As an Associate Professor of Neurology in the Mount Sinai Movement Disorders Center, Dr. Tse sees patients with Parkinson's disease, tremor disorders, restless legs syndrome, dystonia and other movement disorders. She has published several research articles and chapters in research journals and textbooks on the topics of Parkinson's disease, essential tremor, restless legs syndrome and movement disorders in HIV infection. She sees patients with Parkinson's disease and other movement disorders, performs botulinum toxin injections for a wide variety of neurologic conditions and runs clinical research trials in Parkinson disease (PD), deep brain stimulation in PD, botulinum toxin and cervical dystonia.
Dr. Tse is a diplomate of the American Board of Psychiatry and Neurology, and a diplomate of the American Academy of Electrodiagnostic Medicine.
Dr. Tse and her research team are committed to providing our patients with access to research studies that may lead to new breakthroughs in movement disorders research and treatment. Please see below for her current active research studies. For more information, please contact our research coordinator Christina Rosario at phone 212 241 5329 or email: [email protected]
Certifications
Am Board of Electrodiagnostic Medicine
Neurology, American Board of Psychiatry and Neurology
Clinical Focus
- Ataxia
- Benign Essential Tremor
- Botulinum Toxin Injections
- Cervical Dystonia
- Chorea
- Dystonia
- Hemifacial Spasm
- Impaired Gait
- Lewy Body Disease
- Multiple System Atrophy
- Myoclonus
- Parkinson's Disease
- Restless Legs Syndrome
- Spasticity
- Tardive Dyskinesia
- Tremor
- Writers' Cramp
Research Topics
Neurology, Neuromodulation, Parkinson's Disease
Education
MD, S.U.N.Y., Stony Brook Sch. of Med
Internship, Internal Medicine
Mount Sinai Hospital
Residency, Neurology
Mount Sinai Hospital
Fellowship, Neuromuscular Disease and Clinical Neurophysiology
Cornell University Medical College
Languages
English, Chinese (Cantonese), Spanish
Research
Current Research Topics
Our research team includes: Mindy Lopez, CCRC, ACRP-PM, Clinical Research Manager Joan Bratton, BA, Clinical Research Associate Christina Rosario, BA, Clinical Research Coordinator II • A Phase 3, Twelve-week, Multi-Center, Multinational, Randomized, Double-Blind, Double-Dummy, Parallel Group Study to Determine the Efficacy, Safety and Tolerability of P2B001 Once Daily Compared to its Individual Components in Subjects With Early Parkinson's Disease and to a Calibration Arm of Pramipexole ER. • An Open-Label, Phase 3 Study Examining the Long-Term Safety, Tolerability and Efficacy of APL-130277 in Levodopa Responsive Patients with Parkinson's Disease Complicated by Motor Fluctuations ("OFF" Episodes) • A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center Trial to Evaluate the Efficacy and Safety of a Single Treatment of DaxibotulinumtoxinA for Injection in Adults with Isolated Cervical Dystonia (ASPEN-1) • A Phase 3, Open-Label, Multi-Center Trial to Evaluate the Long-Term Safety and Efficacy of Repeat Treatments of DaxibotulinumtoxinA for Injection in Adults with Isolated Cervical Dystonia (ASPEN-OLS) • RESTORE: A clinical study of patients with symptomatic neuRogenic orthostatic hypotEnsion to assess Sustained effecTs Of dRoxidopa thErapy • A Randomized, Parallel-group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of SEP-363856 in Subjects with Parkinson's Disease Psychosis • A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Intravenously Administered BIIB092 in Participants with Progressive Supranuclear Palsy • PL101-LID201 - A 14 week, double-blind, randomized three arm, parallel group study to assess the efficacy and safety of two doses of pridopidine versus placebo for the treatment of levodopa induced dyskinesias in Patients with Parkinson's disease.
Publications
Recent Artifacts:
- Serum antigliadin antibodies in cerebellar ataxias: a systematic review and meta-analysis.
- New onset progressive chorea with elevated striational antibody titers.
- Deep brain stimulation and oropharyngeal dysfunction in Parkinson's disease: a case report.
- Emotional processing affects movement speed.
- Differential role of dopamine in emotional attention and memory: evidence from Parkinson's disease.
- Preserved emotional modulation of motor response time despite psychomotor slowing in young-old adults.
- Skin picking in Parkinson's disease: a behavioral side-effect of dopaminergic treatment?
- The pattern of cognitive-functional decline in elderly essential tremor patients: an exploratory-comparative study with Parkinson's and Alzheimer's disease patients.
- Subthalamic deep brain stimulation and impulse control in Parkinson's disease.
- The effects of withdrawal of dopaminergic medication in nursing home patients with advanced parkinsonism.
Patient Experience Rating
The Patient Experience Star Rating reflects our patients perception of how well their Mount Sinai physician communicated with them during an office visit. The Star Rating is based on patient responses to three questions on the Clinician & Group CAHPS (CG-CAHPS) Survey, a standardized questionnaire developed by Medicare. Responses are measured on a scale of 1 to 5, with 5 being the best score.
★★★★★ 4.8 out of 5
Explains in a way you understand
★★★★★ 4.9 out of 5
Listens carefully
★★★★★ 4.8 out of 5
Likelihood to recommend
Industry Relationships
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr.Tse did not report having any of the following types of financial relationships with industry during 2018 and/or 2019: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Insurance Information
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.